產(chǎn)品名稱 |
Kasumi-6 |
商品貨號 |
B209465 |
Organism |
Homo sapiens, human |
Tissue |
peripheral blood |
Cell Type |
myeloblast |
Product Format |
frozen |
Morphology |
myeloid leukemia |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Disease |
acute myeloid leukemia, subtype M2 |
Age |
64 years adult |
Gender |
male |
Ethnicity |
Japanese |
Applications |
The Kasumi-6 cell line can serve as a model to study the cellular and molecular biology of the non-t(8;21) M2 type of myeloid leukemia and can elucidate the role of mutated C/EBPalpha in leukemogenesis.
|
Storage Conditions |
liquid nitrogen vapor phase |
Karyotype |
45, XY,-9,add(12)(p11),add(13)(p11)
Ref Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245 |
Derivation |
The cell line was established from the blast cells of a myeloperoxidase-negative patient with relapsed acute myeloid leukemia (AML), FAB M2. The patient had received prior chemotherapy. |
Clinical Data |
64 years adult
Japanese
male
|
Antigen Expression |
CD33+, CD13+, CD11b+, HLA-DR+, CD3-, CD14-, CD19-, CD41-, CD34 |
Genes Expressed |
Myeloperoxidase, negative C/EBP-alpha, hemizygous mutation protein positive
|
Comments |
Both the original leukemic cells and the Kasumi-6 cell line harbor a hemizygous point mutation in the gene encoding the CCAAT/enhancer binding protein alpha (C/EBPalpha), a critical myeloid transcriptional factor.
The cells express C/EBPalpha protein but lack C/EBPalpha binding activity.
12-O-tetradecanoylphorbol-13-acetate (TPA) induces Kasumi- 6 cells to differentiate into adherent, monocytoid appearing cells.
Differentiation Inducers: TPA |
Complete Growth Medium |
RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate supplemented with 2 ng/ml human recombinant granulocyte macrophage colony stimulating factor (GM-CSF) and 20% fetal bovine serum
|
Subculturing |
Cultures can be established by centrifugation with subsequent resuspension at 2 x 105 viable cells/mL.
Maintain cell density between 2 x 105 and 1.5 x 106 viable cells/mL.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density). |
Cryopreservation |
Freeze medium: Complete growth medium supplemented with 10% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase |
Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
STR Profile |
Amelogenin: X,Y CSF1PO: 10,12 D13S317: 8,12 D16S539: 9,10 D5S818: 11 D7S820: 9,11 THO1: 6,9 TPOX: 8,9 vWA: 17 |
Population Doubling Time |
55 hrs |
Name of Depositor |
H Asou |
Year of Origin |
January 1999 |
References |
Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245
Asou H, et al. Establishment of the acute myeloid leukemia cell line Kasumi-6 from a patient with a dominant-negative mutation in the DNA-binding region of the C/EBPalpha gene. Genes Chromosomes Cancer 36: 167-174, 2003. PubMed: 12508245
|